Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
Ironwood Pharmaceuticals (IRWD) was downgraded by Zacks Research from "strong-buy" to "hold".
A Look At Ironwood Pharmaceuticals (IRWD) Valuation After Q4 2025 Results And 2026 Revenue Guidance [Yahoo! Finance]
Ironwood Pharmaceuticals (IRWD) had its "hold" rating reaffirmed by Jefferies Financial Group Inc..
Ironwood Pharmaceuticals (IRWD) had its price target raised by Citizens Jmp from $8.00 to $10.00. They now have a "market outperform" rating on the stock.